

Asthma Diagnosis and Monitoring QIP



www.smartrespiratory.com

Monitor Asthma Status Between Consultations





QIP 1 - Diagnose or Re-Assess Asthma Referrals with Smart Asthma Home **Diagnostic Kit**

Problem

- · Asthma is difficult to diagnose as a consequence, one-third of asthma patients are misdiagnosed and 60% of CYP on asthma treatment do not have a diagnosis
- Asthma diagnosis hinges on "variable airway obstruction" and requires multiple observations
- Diagnosis is not conclusive if patients are Spirometry and FeNO tested when their asthma is inactive. BTS recommend targeting asthma during periods when asthma is "active"
- · Symptoms often necessitate trial treatment which further obfuscates tests
- NICE NG80 Asthma Diagnostic Guideline states - "If diagnostic uncertainty remains after spirometry and FeNO, monitor peak flow variability for 2 to 4 weeks"

Solution

- Smart sensors and electronic diary capture PEF diurnal variability
- Show Bronchodilator Reversibility in patients on Salbutamol
- Record symptoms to assure periods of active asthma are captured
- In the absence of asthma symptoms, inhaled corticosteroids are withheld for 24 hours to show PEF variability
- 1 month monitoring and a home diagnostic kit the patient can keep using afterwards
- Confirms or refutes diagnosis of suspected asthma, prior to consultation

Typical Secondary Care Asthma Pathway



Average 3.5 OPAs in 12 months

QIP 2 - Reduce Outpatient Appointments with Smart Asthma Home Monitoring Kit

Problem

- 102,000 asthma hospital episodes p.a. cost the NHS £91m p.a.
- 35% of asthma hospital episodes are readmissions, costing £32m p.a.
- 121,000 ED visits p.a. for asthma, of which 1 in 6 need hospital care again within 2 weeks
- Proactively monitoring asthma reduces hospital utilisation by 57%
- NHS prescribes 500,000 peak flow meters p.a. at cost of £2.6m
- Clinicians only see snapshots of the patient's asthma, during attack or at consultation
- Few patients present usable charts to their clinician, and the charts only show peak flow
- Lack of clinical data leads to increased readmissions, in particular post-ED

Solution

- Patients monitored before and after specialist consultation, for 90 days
- Leads to improved adherence to peak flow monitoring
- Improved adherence to preventer inhalers leads to lower use of reliever inhalers
- Reduce exacerbations by early detection of loss of asthma control
- Monitor post-ED patients after discharge to reduce re-admissions
- Severe asthmatics are monitored to ascertain whether they should be given biologics
- After 3-month Remote Patient Monitoring programme, patient keeps devices
- Patient switches to Self-Monitoring programme
- Integrate with hospital EHR records
- Used in situ and service evaluations across several NHS ICSs, Trusts and PCNs

QIP Steps

- SOP and Outcomes and Measurables Agreement signed by Smart Respiratory and Trust/ICS
- Trust/ICS recruits a minimum of 25 patients
- Patient consents to participating in the QIP, Smart Respiratory contacting them, and receives a Smart Asthma Home Diagnosis Kit, which they can keep after the QIP is completed
- Smart Respiratory helps the patient set up, monitors patient activity and gives the patient a courtesy call if they are not recording regularly
- 72 hours before the appointment, Smart Respiratory emails the home monitoring PDF report to secondary care admin, which can be updated on the day of the appointment by synchronising the link to the dashboard
- Secondary care admin saves the home monitoring report PDF in the patient's HCR
- Upon completing the QIP, the objective is to show improved outcomes that can be shared with the ICS, with a view to scaling up

Secondary Care Episodes

- 102,000 Inpatients Episodes
- 120,000 ED Attendances
 180,000 Outpatient Episodes


90 day Monitoring

High-risk Primary Care

600,000 on 2+ Prednisolone p.a. 900,000 on 6+ SABA p.a.

12 month Self-monitoring

Low-risk Primary Care 8m asthma diagnoses Free Self-management





 CompEx diary events leading to exacerbations and re-admissions PEF Prediction

DSPT, ICO, GDPR, NICE MIB ISO 13485, ORCHA, DPIA, www.smartrespiratory.com antony@smartrespiratory.com

CE mark, MHRA, ISO 23747